1.Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, Falzon D, Floyd K, Gargioni G, Getahun H et al: WHO’s new end TB strategy. Lancet 2015, 385(9979):1799–1801.
2.Organization WH: Gear up to end TB: introducing the end TB strategy. In.: World Health Organization; 2015.
3.Organization WH: Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 2018.
4.Organization WH: Global tuberculosis report 2018: World Health Organization; 2018.
5.Organization WH, others: Global tuberculosis report 2016. 2016.
6.Organization WH, others: Global Tuberculosis Control 2011: WHO Report 2011< http://whqlibdoc. who. int/publications/2011/9789241564380_eng. pdf. Accessed August 2012, 26.
7.Getahun H, Gunneberg C, Granich R, Nunn P: HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 2010, 50 Suppl 3:S201–207.
8.Organization WH: Global Tuberculosis Report. Geneva: World Health Organization; 2014: WHO/HTM/TB/2012.6). Available: http://apps. who. int/iris/bitstream/10665/75938/1/9789241564502_eng. pdf; 2016.
9.Lin PL, Flynn JL: Understanding latent tuberculosis: a moving target. J Immunol 2010, 185(1):15–22.
10.Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Dheda K, Kalantri S: Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. Journal of Occupational Medicine and Toxicology (London, England) 2006, 1:7.
11.Shakak AO, Khalil EA, Musa AM, Salih KA, Bashir AE, Ahmed AH, Idris FE, Elhassan AM: Prevalence of latent tuberculosis infection in Sudan: a case-control study comparing interferon-gamma release assay and tuberculin skin test. BMC public health 2013, 13:1128.
12.Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H: Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control 2009, 58(RR–4):1–207; quiz CE201–204.
13.Godfrey-Faussett P: Policy statement on preventive therapy against tuberculosis in people living with HIV. Report of a meeting held in Geneva 18–20 February 1998. World Health Organization. Global Tuberculosis Programme and UNAIDS. 1998.
14.Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, Metcalfe JZ, Cattamanchi A, Dowdy DW, Dheda K et al: Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clinical microbiology reviews 2014, 27(1):3–20.
15.Farhat M, Greenaway C, Pai M, Menzies D: False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? The International Journal of Tuberculosis and Lung Disease 2006, 10(11):1192–1204.
16.Reichman LB, Hershfield ES: Tuberculosis: a comprehensive international approach: CRC Press; 2000.
17.Andersen P, Munk ME, Pollock JM, Doherty TM: Specific immune-based diagnosis of tuberculosis. The Lancet 2000, 356(9235):1099–1104.
18.Arend SM, van Meijgaarden KE, de Boer K, de Palou EC, van Soolingen D, Ottenhoff TH, van Dissel JT: Tuberculin skin testing and in vitro T cell responses to ESAT–6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii. The Journal of infectious diseases 2002, 186(12):1797–1807.
19.Lewis FM, Marsh BJ, von Reyn CF: Fish tank exposure and cutaneous infections due to Mycobacterium marinum: tuberculin skin testing, treatment, and prevention. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2003, 37(3):390–397.
20.Geluk A, van Meijgaarden KE, Franken KL, Subronto YW, Wieles B, Arend SM, Sampaio EP, de Boer T, Faber WR, Naafs B et al: Identification and characterization of the ESAT–6 homologue of Mycobacterium leprae and T-cell cross-reactivity with Mycobacterium tuberculosis. Infection and immunity 2002, 70(5):2544–2548.
21.Geluk A, van Meijgaarden KE, Franken KL, Wieles B, Arend SM, Faber WR, Naafs B, Ottenhoff TH: Immunological crossreactivity of the Mycobacterium leprae CFP–10 with its homologue in Mycobacterium tuberculosis. Scandinavian journal of immunology 2004, 59(1):66–70.
22.McMurray DN: Mechanisms of anergy in tuberculosis. Chest 1980, 77(1):4–5.
23.Chandrasekaran P, Mave V, Thiruvengadam K, Gupte N, Shivakumar SVBY, Hanna LE, Kulkarni V, Kadam D, Dhanasekaran K, Paradkar M et al: Tuberculin skin test and QuantiFERON-Gold In Tube assay for diagnosis of latent TB infection among household contacts of pulmonary TB patients in high TB burden setting. PloS one 2018, 13(8):e0199360.
24.. In: Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. edn. Geneva; 2018.
25.Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E et al: Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. The European respiratory journal 2015, 46(6):1563–1576.
26.Ayubi E, Doosti-Irani A, Sanjari Moghaddam A, Sani M, Nazarzadeh M, Mostafavi E: The Clinical Usefulness of Tuberculin Skin Test versus Interferon-Gamma Release Assays for Diagnosis of Latent Tuberculosis in HIV Patients: A Meta-Analysis. PloS one 2016, 11(9):e0161983.
27.Talati NJ, Seybold U, Humphrey B, Aina A, Tapia J, Weinfurter P, Albalak R, Blumberg HM: Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC infectious diseases 2009, 9:15.
28.Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM: A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002, 57(9):804–809.
29.Trajman A, Steffen RE, Menzies D: Interferon-gamma release assays versus tuberculin skin testing for the diagnosis of latent tuberculosis infection: an overview of the evidence. Pulmonary medicine 2013, 2013.
30.Lewinsohn DA, Lobato MN, Jereb JA: Interferon-γ release assays: new diagnostic tests for Mycobacterium tuberculosis infection, and their use in children. Current opinion in pediatrics 2010, 22(1):71–76.
31.Kussen GM, Dalla-Costa LM, Rossoni A, Raboni SM: Interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among HIV patients in Brazil. The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases 2016, 20(1):69–75.
32.Latorre I, Martinez-Lacasa X, Font R, Lacoma A, Puig J, Tural C, Lite J, Prat C, Cuchi E, Ausina V et al: IFN-gamma response on T-cell based assays in HIV-infected patients for detection of tuberculosis infection. BMC infectious diseases 2010, 10:348.
33.Balcells ME, Perez CM, Chanqueo L, Lasso M, Villanueva M, Espinoza M, Villarroel L, Garcia P: A comparative study of two different methods for the detection of latent tuberculosis in HIV-positive individuals in Chile. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2008, 12(6):645–652.
34.Babayigit C, Ozer B, Ozer C, Inandi T, Duran N, Gocmen O: Performance of QuantiFERON-TB Gold In-Tube test and Tuberculin Skin Test for diagnosis of latent tuberculosis infection in BCG vaccinated health care workers. Medical science monitor: international medical journal of experimental and clinical research 2014, 20:521–529.
35.Bagheri Amiri F, Saifi M, Gouya MM, Rohani M, Mostafavi E: Comparison of an interferon-gamma release assay and the tuberculin skin test for diagnosis of latent tuberculosis in homeless people in Iran: a cross-sectional study. Infect Dis (Lond) 2015, 47(8):536–541.
36.Campbell JR, Chen W, Johnston J, Cook V, Elwood K, Krot J, Marra F: Latent tuberculosis infection screening in immigrants to low-incidence countries: a meta-analysis. Molecular diagnosis & therapy 2015, 19(2):107–117.
37.Khawcharoenporn T, Apisarnthanarak A, Phetsuksiri B, Rudeeaneksin J, Srisungngam S, Mundy LM: Tuberculin skin test and QuantiFERON-TB Gold In-tube Test for latent tuberculosis in Thai HIV-infected adults. Respirology 2015, 20(2):340–347.
38.Khazraiyan H, Abdi Liaei Z, Emadi Koochak H, Azmoudeh Ardalan F, Ahmadinejad Z, Soltani A: Utility of QuantiFERON-TB Gold In-Tube Test in the Diagnosis of Latent TB in HIV-Positive Patients in a Medium-TB Burden Country. Journal of the International Association of Providers of AIDS Care 2015.
39.Mancuso JD, Mazurek GH, Tribble D, Olsen C, Aronson NE, Geiter L, Goodwin D, Keep LW: Discordance among commercially available diagnostics for latent tuberculosis infection. American journal of respiratory and critical care medicine 2012, 185(4):427–434.
40.Sørensen AL, Nagai S, Houen G, Andersen P, Andersen AB: Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infection and immunity 1995, 63(5):1710–1717.
41.Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK: Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. Journal of bacteriology 1996, 178(5):1274–1282.
42.Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P: Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respiratory research 2006, 7:56.